JPMorgan Downgrades Pacira Pharmaceuticals (PCRX) to Underweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Truist Securities Double Downgrades Pacira Pharmaceuticals (PCRX) to Sell
August 13, 2024 6:06 AM EDTTruist Securities analyst Les Sulewski downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Sell with a price target of $8.00 (from $30.00).
The analyst comments "We revisit our core thesis on PCRX after our follow-up call with KOL conveys generic Exparel launch is... More
